Otizmde İlaç Rehberi

Güler AS, Yazgan MY. Antipsikotikler. Çuhadaroğlu Çetin F. ve ark. editörler. Çocuk ve Ergen Psikiyatrisi Temel Kitabı. 1. baskı. Ankara: Çocuk ve Gençlik Ruh Sağlığı Derneği; 2008. p:617-30.

Stahl SM. Essential Pschopharmacology, Prescriber’s Guide. 5th ed. Cambridge: Cambridge University Pres; 2014.

Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E. Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy. J Child Adolesc Psychopharmacol. 2006;16:575-587

Çocuk ve Ergenlerde Görülen Psikotik Bozuklukların Tedavisinde Kullanılan Atipik Antipsikotikler June 2016, Turkiye Klinikleri Journal of Medical Sciences 1(3):39-53

Vitiello B. Principles in using psychotropic medication in children and adolescents. In: Rey JM (ed) IACAPAP e-Textbook of Child and Adolescent Mental Health. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions, 2012.

Meltzer HY, Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs. Focus (Am Psychiatr Publ). 2021 Jan;19(1):3-13.

McNeil SE, Gibbons JR, Cogburn M. Risperidone. [Updated 2024 Nov 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459313/

Shafiq S, Pringsheim T. Using Antipsychotics for Behavioral Problems in Children. Expert Opin Pharmacother. 2018;19:1475-1488.

Güler AS, Yazgan MY. Antipsikotikler. Çuhadaroğlu Çetin F. ve ark. editörler. Çocuk ve Ergen Psikiyatrisi Temel Kitabı. 1. baskı. Ankara: Çocuk ve Gençlik Ruh Sağlığı Derneği; 2008. p:617-30.

Stahl SM. Antipsikotik ajanlar. stahl’ın temel psikofarmakolojisi sinirbilimsel temeli ve pratik uygulaması. Dördüncü baskı. İstanbul: İstanbul Tıp Kitapevi; 2014. p.129-327.

Correll CU, Antipsycotic Agents: Traditional and Atypical. Martin A., Scahill L., Kratochvil C.J. ed, Pediatric Psychopharmacology Principles and Practice. 2nd ed. New York: Oxford University Press; 2011. p.312-38.

Bristol-Myers Squibb. U.S. Food and Drug Administration approves Abilify (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients (ages 6 to 17 years). November 20, 2009. Available at: http://news.bms.com/press-release/rd-news/us-food-and-drug-administration-approvesabilify-aripiprazole-treatment-irrita. Accessed January 28, 2015.

Abilify (aripiprazole) prescribing information. Princeton, New Jersey: Bristol-Myers Squibb; December 2014. Available at: http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed January 28, 2015.

Dogangün B, Karaçetin G, Kayaalp L. Çocuk ve Ergenlerde Aripiprazol Kullanımıyla İlgili Bir Gözden Geçirme. Çocuk ve Gençlik Ruh Sağlığı Dergisi 2008;15 (3):163-75.

Harrison TS, Perry MC. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 17151736

Kumar B, Prakash A, Sewal RK, et al. Drug therapy in autism: a present and future perspective. Parmacol Rep 2012:64:1291–1304.

Clozaril (clozapine) prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; December 2014. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed January 28, 2015.

Haidary HA, Padhy RK. Clozapine. [Updated 2023 Nov 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535399/

Correll CU, Antipsycotic Agents: Traditional and Atypical. Martin A., Scahill L., Kratochvil C.J. ed, Pediatric Psychopharmacology Principles and Practice. 2nd ed. New York: Oxford University Press; 2011. p.312-38.

Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent.N Engl J Med 1991;324(11):746-54.

Takeuchi H, Powell V, Geisler S, DeSanti M, Fervaha G, Agid O, Kane JM, Remington G. Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand. 2016 Sep;134(3):234-40.

Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliative Med July 2012. Available at: http://www.amepc. org/apm/article/view/1039/1266. Accessed January 28, 2015.

Chokhawala K, Stevens L. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 26, 2023. Antipsychotic Medications.

Haldol (haloperidol) prescribing information. Raritan, New Jersey: Ortho-McNeil Pharmaceutical, Inc.; June 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2009/018701s059lbl.pdf. Accessed January 27, 2015.

MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry 2010;32:443–445.

Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987;16:319–322.

Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008 Apr;28(2):203-9.

Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191.

Rahman S, Marwaha R. Haloperidol. [Updated 2023 Sep 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560892/

Kahlon S, Lee C, Chirurgi R, Worku Hassen G. Angioneurotic edema associated with haloperidol. Case Rep Emerg Med. 2012;2012:725461.

Strain A. Angioedema of the tongue due to haloperidol. Am J Emerg Med. 2022 Mar;53:284.e5-284.e6.

Masiran R. Persistent oromandibular dystonia and angioedema secondary to haloperidol. BMJ Case Rep. 2017 Oct 04;2017

Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci. 2014 Dec;16(4):555-66

Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Mar 01;78(3):270-280.

Ritalin (methylphenidate) prescribing information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; December 2013. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf. Accessed January 29, 2015.

Concerta (extended-release methylphenidate) prescribing information. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; December 2013. Available at: http://www.janssenmd.com/pdf/concerta/CONCERTA_PI.pdf. Accessed January 29, 2015.

Trenque T, Herlem E, Abou Taam M, Drame M. Methylphenidate off-label use and safety. Springerplus. 2014;3:286.

Thorpy MJ, Hiller G. The Medical and Economic Burden of Narcolepsy: Implications for Managed Care. Am Health Drug Benefits. 2017 Jul;10(5):233-241.

Capp PK, Pearl PL, Conlon C. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother. 2005 May;5(3):325-31.

Verghese C, Patel P, Abdijadid S. Methylphenidate. [Updated 2024 Oct 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482451/

Subcommittee on Attention-Deficit/Hyperactivity Disorder. Steering Committee on Quality Improvement and Management. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov;128(5):1007-22.

Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs. 2013 Jul;27(7):531-43.

Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder: a prospective cohort study. Int Clin Psychopharmacol. 2016 Mar;31(2):93-9.

Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, Hafizi S, Perez J, Fernandez-Egea E, Suckling J, Jones PB. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 19;370(1677):20140214.

Effexor XR (extended-release venlafaxine hydrochloride) prescribing information. Philadelphia, Pennsylvania: Wyeth Pharmaceuticals Inc; December 2014. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=100. Accessed January 30, 2015.

Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203.

Guideline Development Panel for the Treatment of Depressive Disorders. Summary of the clinical practice guideline for the treatment of depression across three age cohorts. Am Psychol. 2022 Sep;77(6):770-780.

Dean L. Venlafaxine Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US); Bethesda (MD): Jul 27, 2015.

Alomari NA, Bedaiwi SK, Ghasib AM, Kabbarah AJ, Alnefaie SA, Hariri N, Altammar MA, Fadhel AM, Altowairqi FM. Social Anxiety Disorder: Associated Conditions and Therapeutic Approaches. Cureus. 2022 Dec;14(12):e32687.

Saad MA, El-Sahar AE, Sayed RH, Elbaz EM, Helmy HS, Senousy MA. Venlafaxine Mitigates Depressive-Like Behavior in Ovariectomized Rats by Activating the EPO/EPOR/JAK2 Signaling Pathway and Increasing the Serum Estradiol Level. Neurotherapeutics. 2019 Apr;16(2):404-415.

Zosen D, Kondratskaya E, Kaplan-Arabaci O, Haugen F, Paulsen RE. Antidepressants escitalopram and venlafaxine up-regulate BDNF promoter IV but down-regulate neurite outgrowth in differentiating SH-SY5Y neurons. Neurochem Int. 2023 Oct;169:105571.

Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Alboghobeish S, Amirgholami N, Houshmand G, Cauli O. Venlafaxine prevents morphine antinociceptive tolerance: The role of neuroinflammation and the l-arginine-nitric oxide pathway. Exp Neurol. 2018 May;303:134-141.

Castrén E, Monteggia LM. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol Psychiatry. 2021 Jul 15;90(2):128-136.

Singh D, Saadabadi A. Venlafaxine. [Updated 2024 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535363/

Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: venlafaxine pathway. Pharmacogenet Genomics. 2014 Jan;24(1):62-72

Prozac (fluoxetine) prescribing information. Indianapolis, Indiana:Eli Lilly and Company; July 2014. Available at: http://pi.lilly.com/us/prozac.pdf. Accessed January 30, 2015.

Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459223/

Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019 Apr 12;4(4):CD012680.

Dhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. Biochimie. 2019 Jun;161:73-79.

Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol. 2019 Mar 21;21(4):18.

Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, Golden N, Guarda A, Jackson-Triche M, Manzo L, Mascolo M, Pierce K, Riddle M, Seritan A, Uniacke B, Zucker N, Yager J, Craig TJ, Hong SH, Medicus J. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. Am J Psychiatry. 2023 Feb 01;180(2):167-171.

Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin. 2018 Nov;8(6):275-283.

Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.

Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021 Jan 23;13(2)

Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry. 2019 Oct;13(5):1032-1049.

Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 08;92:109-117.

Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012 May;52(4):437-45.

Savage RA, Zafar N, Yohannan S, et al. Melatonin. [Updated 2024 Feb 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534823/

Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008 Jul;85(3):335-53.

Lalanne S, Fougerou-Leurent C, Anderson GM, Schroder CM, Nir T, Chokron S, Delorme R, Claustrat B, Bellissant E, Kermarrec S, Franco P, Denis L, Tordjman S. Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. Int J Mol Sci. 2021 Feb 2;22(3):1490. doi: 10.3390/ijms22031490. PMID: 33540815; PMCID: PMC7867370.

Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The Safety of Melatonin in Humans. Clin Drug Investig. 2016 Mar;36(3):169-75.

Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014 Oct 01;37(10):1715-9.

Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci. 2013 Apr 22;14(4):8638-83.

Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res, 42:28-42, 2007.

Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015 Aug;71(8):901-9.